Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	May 31, 2018	Apr. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Issuance of common stock, value	$ 75,000
Issuance of common stock, shares	51,988
Accrued expenses			$ 0	$ 250,000
Operating lease term of contract			37 months
Operating lease rent increase in future			$ 7,057
Vaya Pharma, Inc. [Member]
Issuance of common stock, value		$ 250,000
Issuance of common stock, shares		210,084
Pharmaceutical Development Agreement [Member]
Commitments, description			The Amendment, we and Windlas agreed to amend the Development Agreement to reflect our agreement to issue to Windlas, and Windlas' agreement to accept from us, in lieu of cash payments with respect to forty percent (40%) of the total amount reflected on invoices sent from time to time by Windlas to us, shares of our common stock having an aggregate value equal to forty percent (40%) of such invoiced amount (with the remaining portion of the invoiced amount being paid in cash).
Cash payments percentage			40.00%
Operating lease rent expenses			$ 6,458
Pharmaceutical Development Agreement [Member] | Maximum [Member]
Issuance of common stock, value			$ 2,000,000